NICE Supports Servier’s Cancer Drug

The UK’s drug pricing watchdog is recommending NHS reimburse for Servier’s metastatic colorectal cancer drug Lonsurf, provided the company offers the drug at a discounted price.

The UK’s National Institute for Health and Care Excellence’s decision marks the first positive appraisal of a third- or subsequent-line treatment for metastatic colorectal cancer, which often becomes resistant to therapies.